Prostate Cancer Blog - malecare.org

From the 2013 2013 Genitourinary Cancers Symposium: High-Risk Prostate Cancer Treated with Pelvic Radiotherapy and 36 Versus 18 Months of Androgen Blockade

Men who are diagnosed with high risk prostate cancer, meaning they are more likely to develop advanced prostate cancer are usually treated with Radiotherapy (RT) and long term androgen blockade (AB). Currently, we do not know what is the optimal duration of AB. Looking at this problem, the researchers conducted a randomized study to compare [...]

By Malecare|2013-02-17T10:43:04-05:00February 17th, 2013|adjuvant therapy, Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Drugs & Treatments, Hormone Therapy, Radiotherapy, Uncategorized|0 Comments

Two More Provenge Related Abstracts from the 2013 ASCO GU Symposium

More on Sipuleucel-T (Provenge) from the 2013 The last two abstracts that I want to speak about that were presented at the conference that pertained to Provenge speak to its efficacy. The first looks at changes in circulating tumor cells (CTC) and the second to the onset of the use of opioid painkillers. Abstract #40 [...]

By Malecare|2017-10-19T10:50:08-04:00February 15th, 2013|Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Drugs & Treatments, inflammation, Pain, Provenge, Research, Uncategorized, Understanding APC|0 Comments

From the 2013 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium – News of Provenge

Currently in Orlando Florida the 2013 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium is in progress. There are a number of very interesting abstracts that pertain to those of us who have advanced prostate cancer. In the course of the next few days I will be reviewing a number of these that I [...]

By Malecare|2020-02-04T08:56:36-05:00February 14th, 2013|abiraterone acetate, Advanced Prostate Cancer, ASCO, Bio Chemical Recurrence, Combination Therapy, Drugs & Treatments, Hormone Therapy, Research, Uncategorized|0 Comments

Great News for the Advanced Prostate Cancer Community – The FDA Grants a Priority Review for Radium-223 Dichloride (Alpharadin)

Some more good news for the advanced prostate cancer community was announced today. Bayer HealthCare announced that the U.S. Food and Drug Administration (FDA) has granted priority review to their New Drug Application (NDA) filed in December 2012 for the investigational oncology compound radium-223 dichloride (radium-223). The application is under review for the treatment of [...]

By Malecare|2020-02-04T08:22:15-05:00February 13th, 2013|Advanced Prostate Cancer, Alpharadin (radium-223), Clinical Trials, Clinical Trials, FDA, General Information, Uncategorized|0 Comments

Knowing Good from Bad Information Published on the Internet

We all use the Internet to learn about our prostate cancer, your reading this post confirms this statement. The Internet can be a useful tool for finding information and connecting with other patients and caregivers. However, it can also be a nightmare of unreliable misinformation. Understanding what is credible, accurate and reliable information about prostate [...]

By Malecare|2021-02-17T11:03:16-05:00February 12th, 2013|Advanced Prostate Cancer, General Information, How We Live, Uncategorized, Understanding APC|0 Comments